Is Bio Rad Stock a Good Investment?
Bio Rad Investment Advice | BIO |
- Examine Bio Rad's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Bio Rad's leadership team and their track record. Good management can help Bio Rad navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Life Sciences Tools & Services space and any emerging trends that could impact Bio Rad's business and its evolving consumer preferences.
- Compare Bio Rad's performance and market position to its competitors. Analyze how Bio Rad is positioned in terms of product offerings, innovation, and market share.
- Check if Bio Rad pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Bio Rad's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Bio Rad Laboratories stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Bio Rad Laboratories is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Very steady | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
Examine Bio Rad Stock
Researching Bio Rad's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 16.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.18. Some equities with similar Price to Book (P/B) outperform the market in the long run. Bio Rad Laboratories has Price/Earnings To Growth (PEG) ratio of 1.19. The entity recorded a loss per share of 65.35. The firm had not issued any dividends in recent years. Bio Rad had 2:1 split on the 8th of March 2002.
To determine if Bio Rad is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Bio Rad's research are outlined below:
| Bio Rad Laboratories generated a negative expected return over the last 90 days | |
| The company reported the last year's revenue of 2.57 B. Reported Net Loss for the year was (99.4 M) with profit before taxes, overhead, and interest of 1.38 B. | |
| Over 85.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from prnewswire.com: Dignify Therapeutics Highlights Clinical Development Plans at BIO CEO Investor Conference |
Bio Rad Quarterly Long Term Debt |
|
Bio Rad uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Bio Rad Laboratories. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Bio Rad's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 15th of February 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 15th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Bio Rad's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Bio Rad's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
1993-02-12 | 1992-12-31 | 0.07 | 0.06 | -0.01 | 14 | ||
1994-02-09 | 1993-12-31 | 0.09 | 0.13 | 0.04 | 44 | ||
1993-04-28 | 1993-03-31 | 0.1 | 0.14 | 0.04 | 40 | ||
1996-05-01 | 1996-03-31 | 0.34 | 0.39 | 0.05 | 14 | ||
1995-08-02 | 1995-06-30 | 0.22 | 0.27 | 0.05 | 22 | ||
1998-12-01 | 1998-09-30 | 0.14 | 0.08 | -0.06 | 42 | ||
1995-11-01 | 1995-09-30 | 0.17 | 0.23 | 0.06 | 35 | ||
1995-02-08 | 1994-12-31 | 0.13 | 0.19 | 0.06 | 46 |
Bio Rad Target Price Consensus
Bio target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Bio Rad's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 6 | Buy |
Most Bio analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Bio stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Bio Rad Laboratories, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationBio Rad Target Price Projection
Bio Rad's current and average target prices are 277.16 and 404.33, respectively. The current price of Bio Rad is the price at which Bio Rad Laboratories is currently trading. On the other hand, Bio Rad's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Bio Rad Market Quote on 17th of February 2025
Target Price
Analyst Consensus On Bio Rad Target Price
Bio Rad Analyst Ratings
Bio Rad's analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Bio Rad stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Bio Rad's financials, market performance, and future outlook by experienced professionals. Bio Rad's historical ratings below, therefore, can serve as a valuable tool for investors.Know Bio Rad's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Bio Rad is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Bio Rad Laboratories backward and forwards among themselves. Bio Rad's institutional investor refers to the entity that pools money to purchase Bio Rad's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Ubs Asset Mgmt Americas Inc | 2024-09-30 | 441.1 K | Ariel Investments, Llc | 2024-09-30 | 378.7 K | Geode Capital Management, Llc | 2024-09-30 | 323.9 K | Southeastern Asset Management Inc | 2024-09-30 | 318.3 K | Parnassus Investments Llc | 2024-12-31 | 310.9 K | Sei Investments Co | 2024-12-31 | 271.4 K | Bank Of New York Mellon Corp | 2024-12-31 | 267.3 K | Westfield Capital Management Company, L.p. | 2024-12-31 | 264.6 K | Thompson, Siegel & Walmsley Llc | 2024-12-31 | 258.2 K | Blackrock Inc | 2024-09-30 | 1.9 M | Vanguard Group Inc | 2024-12-31 | 1.9 M |
Bio Rad's market capitalization trends
The company currently falls under 'Mid-Cap' category with a total capitalization of 7.94 B.Market Cap |
|
Bio Rad's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.05) | (0.05) | |
| Return On Capital Employed | (0.58) | (0.55) | |
| Return On Assets | (0.06) | (0.06) | |
| Return On Equity | (0.28) | (0.27) |
Determining Bio Rad's profitability involves analyzing its financial statements and using various financial metrics to determine if Bio Rad is a good buy. For example, gross profit margin measures Bio Rad's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Bio Rad's profitability and make more informed investment decisions.
Bio Rad's Earnings Breakdown by Geography
Evaluate Bio Rad's management efficiency
Bio Rad Laboratories has Return on Asset of 0.0155 % which means that on every $100 spent on assets, it made $0.0155 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.2409) %, meaning that it generated no profit with money invested by stockholders. Bio Rad's management efficiency ratios could be used to measure how well Bio Rad manages its routine affairs as well as how well it operates its assets and liabilities. As of the 17th of February 2025, Return On Tangible Assets is likely to grow to -0.05. In addition to that, Return On Capital Employed is likely to grow to -0.55. At this time, Bio Rad's Debt To Assets are very stable compared to the past year. As of the 17th of February 2025, Fixed Asset Turnover is likely to grow to 5.53, while Intangible Assets are likely to drop about 188.7 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (99.06) | (94.10) | |
| Tangible Book Value Per Share | (99.06) | (94.10) | |
| Enterprise Value Over EBITDA | 35.10 | 36.86 | |
| Price Book Value Ratio | 1.41 | 2.13 | |
| Enterprise Value Multiple | 35.10 | 36.86 | |
| Price Fair Value | 1.41 | 2.13 | |
| Enterprise Value | 952.4 M | 1 B |
The operational strategies employed by Bio Rad management play a crucial role in its market positioning. Assessing these strategies alongside financial data helps us evaluate the stock's investment potential.
Beta 0.906 |
Basic technical analysis of Bio Stock
As of the 17th of February 2025, Bio Rad shows the Standard Deviation of 2.51, mean deviation of 1.77, and Risk Adjusted Performance of (0.11). Bio Rad Laboratories technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Bio Rad's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Bio Rad insiders, such as employees or executives, is commonly permitted as long as it does not rely on Bio Rad's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Bio Rad insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Michael Crowley a day ago Disposition of 298 shares by Michael Crowley of Bio Rad at 4.6 subject to Rule 16b-3 | ||
Andrew Last over three weeks ago Disposition of 279 shares by Andrew Last of Bio Rad at 4.6 subject to Rule 16b-3 | ||
Allison Schwartz over three months ago Disposition of tradable shares by Allison Schwartz of Bio Rad at 4.6 subject to Rule 16b-3 | ||
Ilan Daskal over three months ago Acquisition by Ilan Daskal of 456 shares of Bio Rad subject to Rule 16b-3 | ||
Michael Crowley over six months ago Acquisition by Michael Crowley of 520 shares of Bio Rad subject to Rule 16b-3 | ||
Michael Crowley over six months ago Disposition of 298 shares by Michael Crowley of Bio Rad at 4.6 subject to Rule 16b-3 | ||
Michael Crowley over six months ago Acquisition by Michael Crowley of 433 shares of Bio Rad subject to Rule 16b-3 |
Bio Rad's Outstanding Corporate Bonds
Bio Rad issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Bio Rad Laboratories uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Bio bonds can be classified according to their maturity, which is the date when Bio Rad Laboratories has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| BIO 33 15 MAR 27 Corp BondUS090572AR99 | View | |
| BIO 37 15 MAR 32 Corp BondUS090572AQ17 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Understand Bio Rad's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Bio Rad's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.11) | |||
| Market Risk Adjusted Performance | (0.62) | |||
| Mean Deviation | 1.77 | |||
| Coefficient Of Variation | (623.79) | |||
| Standard Deviation | 2.51 | |||
| Variance | 6.29 | |||
| Information Ratio | (0.16) | |||
| Jensen Alpha | (0.41) | |||
| Total Risk Alpha | (0.42) | |||
| Treynor Ratio | (0.63) | |||
| Maximum Drawdown | 10.58 | |||
| Value At Risk | (4.40) | |||
| Potential Upside | 2.91 | |||
| Skewness | (1.05) | |||
| Kurtosis | 3.39 |
| Risk Adjusted Performance | (0.11) | |||
| Market Risk Adjusted Performance | (0.62) | |||
| Mean Deviation | 1.77 | |||
| Coefficient Of Variation | (623.79) | |||
| Standard Deviation | 2.51 | |||
| Variance | 6.29 | |||
| Information Ratio | (0.16) | |||
| Jensen Alpha | (0.41) | |||
| Total Risk Alpha | (0.42) | |||
| Treynor Ratio | (0.63) | |||
| Maximum Drawdown | 10.58 | |||
| Value At Risk | (4.40) | |||
| Potential Upside | 2.91 | |||
| Skewness | (1.05) | |||
| Kurtosis | 3.39 |
Consider Bio Rad's intraday indicators
Bio Rad intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Bio Rad stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 0.0937 | |||
| Daily Balance Of Power | (1.03) | |||
| Rate Of Daily Change | 0.9 | |||
| Day Median Price | 287.83 | |||
| Day Typical Price | 284.27 | |||
| Market Facilitation Index | 28.31 | |||
| Price Action Indicator | (25.26) | |||
| Period Momentum Indicator | (29.20) | |||
| Relative Strength Index | 36.55 |
Bio Rad Corporate Filings
10K | 14th of February 2025 Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance | ViewVerify |
8K | 13th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 20th of December 2024 Other Reports | ViewVerify | |
13A | 14th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
Bio Stock media impact
Far too much social signal, news, headlines, and media speculation about Bio Rad that are available to investors today. That information is available publicly through Bio media outlets and privately through word of mouth or via Bio internal channels. However, regardless of the origin, that massive amount of Bio data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Bio Rad news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Bio Rad relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Bio Rad's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Bio Rad alpha.
Bio Rad Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Bio Rad can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Bio Rad Laboratories Historical Investor Sentiment
Investor biases related to Bio Rad's public news can be used to forecast risks associated with an investment in Bio. The trend in average sentiment can be used to explain how an investor holding Bio can time the market purely based on public headlines and social activities around Bio Rad Laboratories. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Bio Rad's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Bio Rad and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Bio Rad news discussions. The higher the estimate score, the more favorable the investor's outlook on Bio Rad.
Bio Rad Corporate Directors
| Jeffrey Edwards | Independent Director | Profile | |
| Tania DeVilliers | Corporate Director | Profile | |
| Arnold Pinkston | Independent Director | Profile | |
| Alice Schwartz | Director | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bio Rad Laboratories. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bio Rad. If investors know Bio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bio Rad listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 5.412 | Earnings Share (65.35) | Revenue Per Share | Quarterly Revenue Growth (0.02) | Return On Assets |
The market value of Bio Rad Laboratories is measured differently than its book value, which is the value of Bio that is recorded on the company's balance sheet. Investors also form their own opinion of Bio Rad's value that differs from its market value or its book value, called intrinsic value, which is Bio Rad's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bio Rad's market value can be influenced by many factors that don't directly affect Bio Rad's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Bio Rad's value and its price, as these two are different measures arrived at by various means. Investors typically determine if Bio Rad is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bio Rad's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.